Nulibry (Fosdenopterin Hydrobromide) Patent Expiration, LOE Window & CMS Spending

Nulibry (Fosdenopterin Hydrobromide) by Sentynl Therapeutics: FDA Orange Book LOE 2029-04-09, 0 AB generics, $6.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSentynl Therapeutics
FDA Application & PathwayN214018 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-04-09
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.3M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$6.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel